Exploring the role of the inflammasomes on prostate cancer: Interplay with obesity
-
Published:2023-10-11
Issue:6
Volume:24
Page:1165-1187
-
ISSN:1389-9155
-
Container-title:Reviews in Endocrine and Metabolic Disorders
-
language:en
-
Short-container-title:Rev Endocr Metab Disord
Author:
Pérez-Gómez Jesús M.ORCID, Montero-Hidalgo Antonio J.ORCID, Fuentes-Fayos Antonio C.ORCID, Sarmento-Cabral AndréORCID, Guzmán-Ruiz RocioORCID, Malagón María M.ORCID, Herrera-Martínez Aura D.ORCID, Gahete Manuel D.ORCID, Luque Raúl M.ORCID
Abstract
AbstractObesity is a weight-related disorder characterized by excessive adipose tissue growth and dysfunction which leads to the onset of a systemic chronic low-grade inflammatory state. Likewise, inflammation is considered a classic cancer hallmark affecting several steps of carcinogenesis and tumor progression. In this regard, novel molecular complexes termed inflammasomes have been identified which are able to react to a wide spectrum of insults, impacting several metabolic-related disorders, but their contribution to cancer biology remains unclear. In this context, prostate cancer (PCa) has a markedly inflammatory component, and patients frequently are elderly individuals who exhibit weight-related disorders, being obesity the most prevalent condition. Therefore, inflammation, and specifically, inflammasome complexes, could be crucial players in the interplay between PCa and metabolic disorders. In this review, we will: 1) discuss the potential role of each inflammasome component (sensor, molecular adaptor, and targets) in PCa pathophysiology, placing special emphasis on IL-1β/NF-kB pathway and ROS and hypoxia influence; 2) explore the association between inflammasomes and obesity, and how these molecular complexes could act as the cornerstone between the obesity and PCa; and, 3) compile current clinical trials regarding inflammasome targeting, providing some insights about their potential use in the clinical practice.
Funder
Ministerio de Ciencia, Innovación y Universidades
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference236 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660. 2. Eeles RA, Dearnaley DP, ArdernJones A, Shearer RJ, Easton DF, Ford D, Edwards S, Dowe A, Anderson J, Archibold J, Bailey M, Barker C, Bellringer J, Bishop DT, Bishop M, Bolger J, Boyd J, Budd D, Butler M, Brookstein R, Charig C, Conn I, Cranston C, Crundwell M, Das G, Doble A, Duncan W, Duchesne J, Eccles D, Fawcett D, Fisher C, Fletcher M, Fowler JW, Gallegos C, Ghaznavi A, Gilbert H, Glaholm J, Gordon E, Hampson S, Hanbury DC, Hargreave T, Harland S, Harrison GS, Harrison NW, Hart JL, Hehir M, Hendry W, Higgins A, Hopper J, Horwich A, Hughes M, Irving S, James N, Jenkins IL, Jones C, Key T, Kaisary A, Kirby R, Kirk D, Lee J, Lemberger R, Lloyd S, Lynch M, Malone PR, Mansi J, Mason M, McEwan AB, McNicholas TA, Moffat LEF, Morgan RJ, Murday V, Muir G, Munson KW, Murray K, Murrell S, Newman H, Oboyle PJ, Odonoghue E, Notley RG, Pengelly A, Philip T, Plail R, Powell C, Russell J, Read G, Reddy PJ, Richmond W, Roberts T, Rowley K, Rouse AD, Russell RM, Ryan P, Senanayake L, Sandhu D, Shridhar P, Shweitzer R, Shearer R, Smith J, Smith P, Stockdale A, Stower M, Thomas P, Terry T, Thurston A, Tullock D, Turner G, Wallace M, Weston P, Whelan P, Whillis D, Wilson R, Williams G, Woodhouse C. Familial prostate cancer: The evidence and the Cancer Research Campaign British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Br J Urol. 1997;79:8–14. https://doi.org/10.1111/j.1464-410X.1997.tb00795.x. 3. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, Sciarra A, Tubaro A. The controversial relationship between benign prostatic hyperplasia and prostate cancer: The role of inflammation. Eur Urol. 2011;60(1):106–17. https://doi.org/10.1016/j.eururo.2011.03.055. 4. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: Weighing the evidence. Eur Urol. 2013;63(5):800–9. https://doi.org/10.1016/j.eururo.2012.11.013. 5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|